美股A股
StockGist

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ · Healthcare · Biotechnology
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid…
$165.04+5.36%
报价 2026-11-13
市值
$22.11B
EV
$40.29B
PE (TTM)
129.2x
预期 PE (FY2026)
9.0x
52 周区间距高点 -65.1%
$151.64$473.29

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology

爆发潜力

2026-11-13

不在筛选范围:industry: Biotechnology

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
ALNYAlnylam Pharmaceuticals, Inc.$22.11B+5.4%+45.1%81.7%129.2x85.2x44.1x
REGNRegeneron Pharmaceuticals, Inc.$98.82B+0.5%+31.5%85.8%19.8x15.1x26.6x
CICigna Corporation$78.26B+0.2%+5.9%9.5%11.7x7.8x9.5xCheap
CORCencora, Inc.$68.51B+3.0%+4.6%4.3%23.2x13.6x15.1x
CAHCardinal Health, Inc.$64.97B+1.1%+4.1%4.3%31.6x16.9x11.9x
EWEdwards Lifesciences Corporation$61.61B+1.3%+12.7%78.1%44.5x32.6x43.3xGARP
ARGXargenx SE$60.37B-2.2%–89.9%38.2x39.0x58.5x
BDXBecton, Dickinson and Company$59.39B+1.1%+2.4%45.8%25.3x14.7x21.1x
IDXXIDEXX Laboratories, Inc.$55.48B+0.9%+10.8%62.9%47.6x33.7x42.8x
同行中位数––+5.9%54.4%28.5x16.0x23.9x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

暂无季度数据(首次研究运行后填充)。

研究材料